% | $
Quotes you view appear here for quick access.

Protalix BioTherapeutics, Inc. (PLX) Message Board

  • ghostinthemachine81 ghostinthemachine81 Oct 1, 2013 3:43 AM Flag

    PLX's future strategic direction should be focused on maximizing use of their technology

    Announcing a new strategic direction for the company in which they offer the technology for modest upfront fee for a NON-exclusive license plus 5% future royalty on future sales will have all the generic manufacturers knocking on their door. Signing their first deal with South Korea's Hanwha Chemical will cause their stock price to explode. Hanwha is the South Korean biosimilars manufacture that Merck teamed up with to bring its biosimilar version of Amgen's Enbre to market, until the USPTO extended Amgen's patent for another 16 years. Partner with Hanwha and they will get Merck's attention. Merck is ready to stab all these big pharma's in the back and steal their highly profitable drugs sales.

    Sign Teva, Hospira and Celltrion right after Hanwha and Protalix's market cap will instantly grow beyond the takeover aspirations of Pfizer.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.648+0.0020(+0.31%)Jun 29 4:00 PMEDT